Skip to content

AI-Powered Forecasts for Biotech Investors

Home
Tools
Alerts
About
Join ScanScor
Log In
- Panel

ScanScor

The AI Biotech Breakout Prediction Strategy

ScanScor

The AI Biotech Breakout Prediction Strategy

Predictions
Scores
News Stream

pancreatic-cancer

AI Biomed Predictions

IMRX – ASCO Data Will Decide Whether IMRX Earns Its Re-Rating

ScanScor Admin / May 30, 2026

Search

Tools

Predictions
Scores
News Stream

Recent Comments

Recent Comments

4 days ago MNOV – MediciNova Set for S... – MNOV – WATCH ACTIVE Catalyst: MN-001 Phase 2 top-line da... by ScanScor Admin
5 days ago BRTX – Depressed BRTX Await... – BRTX has good news for the science/story, but bad news fo... by ScanScor Admin
5 days ago CHRS – Coherus Oncology Set... – CHRS - QUALIFIED / ACTIVE INTO LATE WINDOW Company: Co... by ScanScor Admin
5 days ago CING – May FDA decision cou... – CING - ACTIVE PRE-PDUFA BUILDUP Qualification: YES Ca... by ScanScor Admin
1 week ago OTLK – May FDA dispute ruli... – post-mortem logic is: OTLK - WHY THE WINDOW ENDS TODAY ... by ScanScor Admin

Recent Posts

IMRX – ASCO Data Will Decide Whether IMRX Earns Its Re-Rating
ACET – Midyear prula-cel data could redefine ACET’s autoimmune narrative
CRDF – ASCO Data Could Decide Cardiff Oncology’s Next Sharp Repricing
ACHV – ACHV Faces Make-or-Break FDA Catalyst With Sharp Upside Potential
AVIR – Phase 3 HCV data could decide Atea’s next rerating

ScanScor empowers traders and investors with instant
AI-driven access to trusted intelligence.

🧠 Powered by real-time AI
🔍 Trained to find the moment before it moves

Terms and Conditions
About
Join the ScanScor Revolution

Disclaimer: ScanScor provides research and educational information only. Nothing on this site is financial advice or a recommendation to buy or sell securities. ScanScor does not provide forecasts or guarantee any outcomes. Past performance is not indicative of future results.

Copyright © 2026 ScanScor

Best viewed on desktop. Mobile optimization coming soon.

Scroll to Top